More Than 200 Companies Advance Trial Management with Veeva CTMS
Rhea-AI Summary
Veeva Systems (NYSE: VEEV) announced that over 200 companies, including 17 of the top 20 biopharmas, are now using Veeva CTMS for clinical trial management. The platform helps streamline trial processes and enhance collaboration as studies become more complex and data-intensive.
The system serves as a central hub for managing study metrics and documents, enabling both insourced and outsourced trial operations while maintaining compliance with global regulations like ICH E6(R2) and (R3). New features include automated CRO-to-sponsor data transfers, improved oversight issue tracking, and enhanced capabilities for managing complex trials.
Veeva CTMS is part of the broader Veeva Clinical Platform, designed to accelerate trial execution and improve operational efficiency. The company continues to enhance the platform through three product releases annually.
Positive
- Strong market penetration with 200+ companies using the CTMS platform
- High-value customer base including 85% of top 20 biopharmas
- Regular platform updates with three annual releases
- New feature rollouts addressing key operational needs
Negative
- None.
News Market Reaction
On the day this news was published, VEEV gained 0.03%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Biopharmas use leading CTMS for improved trial efficiency and collaboration
"Veeva CTMS is the central hub of our trials, allowing study metrics and documents to flow seamlessly across our ecosystem," said Bonne Adams, vice president of operations at Inhibrx. "Using clinical applications on a connected platform saves time and effort for our lean team and improves how we work with CRO partners."
Whether biopharmas insource or outsource trials, clinical teams can use Veeva CTMS to proactively manage studies and quickly identify and address issues. With a flexible and scalable system, companies can accelerate trial execution and deliver high-quality data while maintaining compliance with global regulations like ICH E6(R2) and (R3).
To help biopharmas adapt to trial operating model changes and keep up with evolving regulations, Veeva continues to deliver clinical innovations. New Veeva CTMS advancements include:
- CTMS transfer automates daily data transfers from CROs to sponsors for greater visibility
- Oversight issue tracking and management for faster resolution
- Enhancements to manage insourced, outsourced, and complex trials for speed and agility
"Modern clinical trial management systems should scale easily and support both insourced and outsourced operating models," said Henry Galio, vice president of Veeva CTMS strategy. "To provide this flexibility, we're delivering new capabilities for Veeva CTMS through our three product releases per year, continuously advancing to help the industry work better together and accelerate execution."
With the increased adoption of Veeva CTMS, more companies are simplifying trial operations and maintaining compliance regardless of operating model. Veeva CTMS is part of Veeva Clinical Platform, the most complete and highest-quality platform for faster and more efficient trials. Learn more about Veeva CTMS at SCOPE 2025 booth 916, Feb. 3-6 in
Additional Information
For more on Veeva CTMS, visit: veeva.com/CTMS Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/more-than-200-companies-advance-trial-management-with-veeva-ctms-302362835.html
SOURCE Veeva Systems
FAQ
How many companies are currently using Veeva CTMS for trial management?
What are the key new features added to Veeva CTMS in 2025?
How often does Veeva (VEEV) release updates for its CTMS platform?
What regulatory compliance standards does Veeva CTMS support?
How does Veeva CTMS benefit clinical trial operations?
